[关键词]
[摘要]
目的 分析瑞舒伐他汀对不稳定型心绞痛患者冠状动脉支架植入术后的心肌保护作用。方法 选择2014年1月~2016年5月陕西省核215医院收治的择期行冠状动脉支架植入术的不稳定型心绞痛患者90例为研究对象,根据入院治疗病例号顺序分为观察组和对照组,每组45例,对照组在常规治疗的基础之上加用阿托伐他汀,观察组在常规治疗的基础上加用瑞舒伐他汀,比较两组肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白(cTnI)、人心型脂肪酸结合蛋白(h-FABP)以及超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(INF-γ)、白介素-6(IL-6)白介素-10(IL-10)、白介素-18(IL-18)水平。记录两组治疗过程中的药物不良反应及心脏不良事件发生情况。结果 术后24 h,两组的CK-MB、cTnI水平均较术前显著升高(P<0.05),但观察组的CK-MB、cTnI水平低于对照组(P<0.05),两组h-FABP水平术前术后及组间比较,差异均无统计学意义;术后观察组和对照组的hs-CRP、TNF-α、INF-γ、IL-10、IL-18水平均较术前升高(P<0.05),且对照组的水平均显著高于观察组(P<0.05);术后,观察组的IL-6高于术前,但差异无统计学意义,对照组的IL-6水平显著高于术前和术后观察组(P<0.05)。两组药物不良反应及心脏不良事件发生情况比较,差异无统计学意义。结论 与同剂量阿托伐他汀相比,瑞舒伐他汀改善心肌损伤和炎症状态的效果更优,且不增加不良反应。
[Key word]
[Abstract]
Objective To investigate the myocardial protective effects of rosuvastatin in patients with unstable angina pectoris undergoing coronary stent implantation.Methods Patients (90 cases) with unstable angina pectoris undergoing coronary stent implantation in No. 215 Hospital of Shanxi Nuclear Industry from January 2014 to May 2016 were divided into observation group and control group, 45 cases in each group. Patients in the observation group were treated with rosuvastatin, and patients in the control group were treated with atorvastatin. The levels of CK-MB, cTnI, h-FABP, hs-CRP, TNF-α, INF-γ, IL-6, IL-10, and IL-18 were compared between two groups. Adverse drug reaction and major adverse cardiac events of two groups were recorded.Results After 24 h operation, the levels of CK-MB, cTnI, hs-CRP, TNF-α, INF-γ, IL-10, and IL-18 of two group were significantly higher than those before operation (P<0.05), and those in observation group were significantly lower than control group (P<0.05). There was no difference in h-FABP between two groups before and after operation (P<0.05). The level of IL-6 in the observation group after operation was higher than that before operation, but the difference was not significant (P<0.05); The level of IL-6 in the control group was significantly higher than that before operation and that of observation group (P<0.05); The rates of drug adverse reactions and major adverse cardiac events were similar in two groups.Conclusion Compared with same doseatorvastatin, the effects of rosuvastatin in muscle damage and inflammatory response are better, and do not increase adverse reactions.
[中图分类号]
[基金项目]